1. Home
  2. |Insights
  3. |On the Cyber Frontier of IoT Security

On the Cyber Frontier of IoT Security

Client Alert | 1 min read | 04.11.18

In the Interagency Report on Status of International Cybersecurity Standardization for the Internet of Things (IoT), the National Institute of Standards and Technology (NIST) performed an extensive survey of current cybersecurity standards applicable or potentially applicable to IoT devices. Among the many key findings and discussions, some of the more notable are: (1) NIST elected not to define IoT due to the many varying definitions already in the field (see Annex A); (2) NIST used several functional IoT applications (connected vehicles, consumer devices, health/medical devices, smart buildings and smart manufacturing) to assess current cyber standards and gaps; (3) NIST recognized that no one-size-fits-all standards exist, as specific sectors will have differing risk scenarios and security objectives, thus requiring cyber standards to be tailored; and (4) IoT security should be built around eleven core areas of cybersecurity standardization. Also, NIST is looking for your comments on draft NISTIR 8200 by April 18. To learn more, join us at the IoT National Institute on May 9-10 in Washington, D.C.

Insights

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] ...